Veloryx follow-up: the capital structure, liabilities, and dilution after 2025
The main article showed that Veloryx bought time. This follow-up shows how that time was already redistributed: the $9.813 million liability to issue shares and warrants, the controlling shareholder investment, the 2 million-share right granted after a repaid loan, and the March 2026 private placement all push a large part of any future upside first toward the financiers.
What This Follow-up Is Isolating
The main article made a simple point: after 2025, Veloryx bought itself time, but it still had not bought itself a proven operating business. This follow-up isolates only one layer, the capital structure, and asks a different question: if the defense transition eventually creates value, who actually gets to it first.
The answer starts with four facts. First: at year-end 2025 the balance sheet already carried a $9.813 million liability to issue shares and warrants, while cash stood at only $321k. Second: the controlling shareholder's $3 million loan did not remain a standalone bridge loan. In substance it became the first rung inside a $9 million investment package. Third: even debt that was fully repaid still left an equity sweetener behind, as shown by the right to buy 2 million shares that was granted in January 2026 after another loan had already been paid back. Fourth: in March 2026 another capital layer was added, 13.0 million shares and 6.5 million warrants, before the new strategy had shown operating proof in reported results.
So this is not only a question of how much money came in. It is a question of the price of capital, of seniority inside the upside, and of how much of the future story has already been allocated to the people who financed the bridge year.
The Capital Layers Already Sitting Ahead of Year-end 2025 Shareholders
| Layer | Cash to the company | Securities | Status during and after the period | Economic meaning |
|---|---|---|---|---|
| Controlling shareholder transaction | $9 million in total, after a prior $3 million loan was netted into the deal | 37,428,750 shares and 18,714,375 warrants | Completed in February 2026, with all securities issued by 26 February 2026 | This is no longer temporary liquidity support. It is an ownership layer almost as large as the entire year-end 2025 share base |
| Noa Rabi right | A NIS 1.6 million loan that had already been fully repaid in November 2025 | Right to buy 2,000,000 shares at NIS 0.8 per share until 25 November 2026 | Reported in January 2026 | Even after full repayment, the lender remained with a deep in-the-money equity option |
| March 2026 private placement | NIS 19.501 million of immediate cash, plus about NIS 16.251 million if the warrants are exercised | 13,000,666 shares and 6,500,333 warrants | Approved by the board on 24 March 2026; as of the annual report date, exchange approval had not yet been received | A new equity layer that further widens the upside allocation before the new strategy has shown reported operating proof |
This chart is the accounting core of the story. The $9.813 million liability represented about 82% of total current liabilities, more than 30 times year-end cash, and almost the full negative-equity gap. That is why the wrong reading is to treat the new capital as if it merely helped the company survive. In a material sense, it had already bought itself a durable place in the future ownership stack.
The $3 Million Loan Did Not Bridge the Gap. It Fixed the Entry Price
In June 2025, the controlling shareholder, Alexander Chernilovsky, provided the company with a loan in a shekel amount equal to $3 million, in two $1.5 million tranches, at prime plus 1.5%, and originally due at the end of September 2025. The agreement also included a right to convert into shares, and if the company failed to raise $3 million from other investors by maturity, a right to convert at a 20% discount to the average market price over the prior 15 trading days, subject to a cap at the share price on signing.
On paper, that looks like bridge financing. In substance, by November 2025 it had already been folded into the broader investment package. The amendment to the agreement increased the controlling shareholder's total investment from $3 million to $9 million and explicitly stated that the original loan would be deemed repaid in full by offset once the original $3 million investment tranche was put in place. In other words, the first $3 million did not really return to the company as fresh flexibility. It was converted into the first equity rung inside a larger ownership deal.
That also explains why the company booked such a large liability to issue shares and warrants at year-end. The agreement said the entire package would only be issued after full completion of the investment. So by December 2025 the company was already carrying the economic cost of that package even though part of the cash had not yet been received.
By February 2026 the transaction was fully complete. The controlling shareholder accelerated the final payment, funded the full $9 million, and by 26 February 2026 had received 37,428,750 shares and 18,714,375 warrants. The shares alone were almost as large as the entire year-end 2025 issued share base of 39,494,086 shares.
That chart is no longer theoretical. After the controlling shareholder shares alone, the year-end 2025 shareholders fall to about 51.3% ownership. If the 2 million-share right is exercised and the March placement shares are issued, they fall to about 43.0%. If the major warrant layers are then exercised as well, they are left with only about 33.7%. The certainty level differs across those layers, but the direction is unmistakable.
The $9.813 Million Liability Was Already an Advance Allocation of Value
The most important accounting line in this follow-up is not bank debt and not a covenant. It is the liability to issue shares and warrants. Note 11 explains that the package owed to the investor who kept funding the company would be measured at fair value through profit and loss until completion. That is why, by December 2025, the company was already carrying a $9.813 million liability, up from $4.557 million at initial recognition.
This is not a footnote. In 2025 alone, the remeasurement of that liability created $5.254 million of finance expense, and the income statement separately shows $5.093 million of finance expense directly tied to the liability to issue shares and warrants. Out of total finance expense of $5.643 million, almost all of it came from this layer.
The correct reading is not that Veloryx was hurt by some abstract accounting technicality. The correct reading is that the company paid for time mainly through equity economics. The dilution, and the economic cost of it, did not wait for the formal issuance date. They were already moving through profit and loss while the business itself was still not generating revenue.
That is exactly where the value-capture question becomes real. If the new defense activity or AQ150 later create economic value, part of that value has already been pre-allocated inside a package delivered to the capital provider. The legacy shareholders are not starting from the same line.
Even a Repaid Loan Left Behind a Deep In-the-money Equity Sweetener
The January 2026 event is especially sharp because it does not sit on top of an unpaid debt balance. It sits on top of debt that had already been repaid. Noa Rabi had provided the company with a NIS 1.6 million loan in October 2025. That loan was fully repaid on 25 November 2025. And yet, in January 2026, the company disclosed a non-listed right, granted for no consideration, to buy 2,000,000 shares at NIS 0.8 per share until 25 November 2026.
The figures in that filing are hard to ignore. As of the report date, full exercise of the right would represent 4.67% of the issued share capital after allocation and 3.95% on a fully diluted basis. The share price immediately before the filing was 205.7 agorot, so the exercise price was only about 38.89% of market price. The fair value of the right itself was estimated at NIS 2.618 million.
The economic meaning is simple. Even if one puts aside the legal dispute around the lender's claimed conversion right, the practical outcome is clear. A loan that had already been repaid still ended with a meaningful equity sweetener. The company had to leave substantial upside with the funder even after returning the principal. That is not a technical side event. It is another sign that, during this period, bargaining power sat with the cash provider rather than with the ordinary shareholders.
March 2026 Added Another Layer Without Erasing the Old Ones
On 24 March 2026, the board approved a private placement of NIS 19,500,999 to nine qualified investors. In return, the company would allocate 13,000,666 shares and 6,500,333 warrants exercisable for 12 months at NIS 2.5. The share price set in the raise was NIS 1.5. If the warrants are exercised, the company could receive another roughly NIS 16.251 million.
Precision matters here. As of the annual report date, the placement was not yet fully closed, because exchange approval for listing the securities had not yet been received. So this is not another already-issued dilution layer like the controlling shareholder package. But it is absolutely an approved and signed financing layer, and it shows that even after the full $9 million controlling-shareholder investment was completed in February, the company still needed fresh equity money by March.
This chart also makes the right distinction. The dilution is not a single event. It is a ladder of certainty. The controlling shareholder shares are already in. The Noa Rabi right remains open for exercise. The March 2026 shares were still awaiting exchange approval as stated in the annual report. The warrants are an additional conditional layer. But even without taking every step to its most diluted endpoint, the year-end 2025 shareholders have already moved from owning all of the future to a position where a large part of that future has been pre-allocated to the people who financed the bridge period.
There is also a fair counter-thesis here. Without these capital layers, Veloryx might never have reached any proof point at all. The company ended 2025 with only $321k of cash, negative equity of $10.405 million, and operating cash burn of $10.201 million. In that setup, heavy dilution is better than immediate liquidity failure. But even if one accepts that argument in full, it does not cancel the core conclusion. It sharpens it. Shareholders did not merely pay for time. They paid for very expensive time.
Bottom Line
If Veloryx succeeds in proving out the defense activity, closing Euro Sol, or moving AQ150 onto a commercial path, that value will not arrive to the year-end 2025 shareholders on a blank sheet. It will first have to pass through the capital layers that are already in place: the controlling shareholder's shares and warrants, the 2 million-share right that survived a repaid loan, and the additional private placement that appeared immediately after the $9 million transaction was completed.
That is why the key question from here is not only whether the company can succeed. It is whether it can reach the next proof point without opening another financing layer of the same kind. If the answer is yes, legacy shareholders can still participate meaningfully in the transition. If the answer is no, the value created may keep flowing first to the people who provided the oxygen.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.